Radiance
Register
Register
Register

Project cooperationUpdated on 26 June 2025

Preclinical Immuno-modulatory Drug Development in Oncology

Marc Creus

CEO at abbmira therapeutics AG

Basel, Switzerland

About

The native immune system and particularly tumor associated macrophages (TAMs) are critical in driving response to cancer therapies. Abbmira designs novel synthetic small molecule compounds against a specific molecular target of macrophages that activate TAMs to exert direct anti-tumoral action, whilst signaling to the rest of the immune system to fight the cancer also.

Stage

  • Proposal Idea
  • Proposal under Development

Topic

  • MSCA-PF2025
  • MSCA-DN2025

Type

  • POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
  • DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)

Organisation

abbmira therapeutics AG

Company (SME, Spin-off, Start-up)

Basel, Switzerland

Similar opportunities

  • Expertise

    Preclinical Immuno-Modulatory Drug Development in Oncology

    • CHE - Chemistry
    • LIF - Life Sciences
    • DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
    • POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements

    Marc Creus

    CEO at abbmira therapeutics AG

    Basel, Switzerland

  • Project cooperation

    MSCA-PF: Maxillofacial Oncology Research Group

    • MSCA-PF2025
    • Proposal Idea
    • POSTDOCTORAL FELLOWSHIP: Looking for Fellow

    Elena Dapía Díaz

    International Project Manager at Foundation for Biosanitary Research and Innovation of Asturias (FINBA)

    OVIEDO, (seleccione opción), Spain

  • Project cooperation

    MSCA-PF: Head and Neck Cancer Research Group

    • MSCA-PF2025
    • Proposal Idea
    • POSTDOCTORAL FELLOWSHIP: Looking for Fellow

    Elena Dapía Díaz

    International Project Manager at Foundation for Biosanitary Research and Innovation of Asturias (FINBA)

    OVIEDO, (seleccione opción), Spain